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ABSTRACT
The Polish Society of Colposcopy and Cervical Pathophysiology (PTKiPSM) together with the Polish Society of Gynecologists 
and Obstetricians (PTGiP) issued a final summary of interim guidelines for secondary cervical cancer prevention during the 
SARS-CoV-2 pandemic based on the analysis of the latest directional publications and the authors’ own experiences. The aim 
of the summary is to facilitate the implementation of the most effective possible screening of cervical precancerous lesions 
and cervical cancer due to temporary significant limitation of screening as a consequence of the ongoing epidemiologi-
cal threat. These final guidelines are taking into account the 2020 call of the World Health Organization (WHO) for global 
epidemiological elimination of cervical cancer. The guidelines supplement the interim guidelines of PTKiPSM and PTGiP 
announced in March 2020 on the possible deferral of diagnostic and therapeutic procedures in patients with abnormal 
screening tests results in secondary prevention of cervical cancer in current pandemic.
Key words: cervical cancer prevention; abnormal screening results; HPV testing; cervical cytology; selfsampling; 
SARS-CoV-2 pandemic; guidelines
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The recommendations present the current management 
which may be modified and changed in justified cases, after 
a thorough analysis of a given clinical situation, which in 
the future may constitute the basis for their modification 
and update.
Interim guidelines apply to the period indicated only.
INTRODUCTION
In May 2020, the World Health Organization (WHO) 
called on all institutions in the world involved in the 
cervical cancer prevention to take action to eliminate 
cervical cancer as a population problem by the end of 
the century, which is to reduce the number of cases to 
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a level of a very rare disease (≤ 4 cases/100,000/year). 
According to WHO, European countries should achieve 
this goal earlier, i.e. between 2055 and 2059. WHO has also 
defined goals to be reached in the short term, which will 
allow the achievement of the indicated main goal. The 
year 2030 is the time limit for all countries to meet the 
minimum targets defined by the abbreviation “90–70–90” 
which includes:
•	 covering 90% of girls by the age of 15 with the full vac-
cination against human papillomavirus (HPV),
•	 covering 70% of women with a highly effective screen-
ing test at least twice during their lifetime, in 35 and 
again in 45 years of age,
•	 covering 90% of women with diagnosis of precancerous 
lesions or cervical cancer with appropriate treatment 
and care [1–3].
The European response to WHO’s call is a joint ini-
tiative of the European CanCer Organization (ECCO), the 
European Society of Gynecological Oncology (ESGO) and 
the European Federation for Colposcopy (E.F.C.). The Eu-
ropean proposals for goals that should be achieved by 
2030 have a wider scope and have been specified in relation 
to the WHO base document and include, among others:
•	 covering 90% of girls and boys with the full vaccination 
against HPV by the age of 15,
•	 covering 70% of women in Europe at the indicated age 
by cervical cancer screening using a clinically validated 
test for high-risk human papillomavirus types (HRHPV) 
over the last five years,
•	 providing 90% of women with diagnosis of histologic 
histological high-grade squamous intraepithelial lesions 
(HSIL) with subcategorization to CIN 3 and higher (CIN 
3+) with treatment within 3 months from diagnosis, and 
all women diagnosed with cervical cancer ensure access 
to appropriate oncological care, including palliative care.
The document also points to the uniqueness of the 
challenges related to the SARS-CoV-2 pandemic, including 
the need for European women to access, especially during 
the pandemic, HRHPV self-sampling kits [4].
The Polish response to the WHO’s call is the COLPOSCO-
PY 2020 Project with already published [5, 6] and planned 
for publication guidelines for secondary cervical cancer 
prevention in Poland.
The achievement of the goals set by WHO is obviously 
hindered by the SARS-CoV-2 pandemic that has significantly 
inhibited or limited secondary cancer prevention, including 
cervical cancer. American data indicate a reduction of up to 
94% in the number of cervical cancer screening tests per-
formed between week 10 and week 20 of this year compared 
to previous years. In June, the situation improved slightly, 
setting the screening tests deficit at 67%, which is still a very 
high-level [7]. Polish data for 2020 in the secondary cervical 
cancer prevention financed from public funds are highly 
worrying — 13.84% of the planned female population was 
screened [8]. Data for cervical cancer screening in the oppor-
tunistic model, apart from public funding, are not known.
Interim guidelines related to the pandemic are the reac-
tion of scientific societies to the rapidly changing screening 
reality in this period, which could not be foreseen in the 
planned model of secondary cervical cancer prevention in 
Poland. That consequently means the need to implement 
modifications and updates depending on the changing 
external epidemiological situation [9].
RECOMMENDED CERVICAL CANCER 
SCREENING APPROACH DURING  
THE SARS-COV-2 PANDEMIC
The long-term consequences of limiting or discon-
tinuing the population-based cervical cancer secondary 
prevention tools can be difficult to predict and control. 
In the persistent SARS-CoV-2 pandemic and its unforesee-
able course and completion date, taking into account the 
WHO’s May 2020 call for action on cervical cancer prevention 
and its goals, the following screening approach is temporar-
ily recommended in Polish conditions during the epidemi-
ological threat associated with the SARS-CoV-2 pandemic. 
The overriding immediate goal of these guidelines is to 
achieve in Poland in the time of a pandemic the highest 
possible share of the population covered by screening, op-
timally according to the recommended interim screening 
models, with the most effective diagnostic possible triage 
of patients requiring referral to colposcopy.
The recommended cervical cancer screening in Poland 
during the SARS-CoV-2 pandemic includes the following 
strategies:
1. In the case of an epidemiological situation that allows 
the collection of material from the cervix by a gynecolo-
gist or midwife and the availability of dedicated diag-
nostic-laboratory facilities, liquid-based screening (LBS), 
i.e., the use of a liquid preparation as a carrier of the 
collected cell material, is recommended. LBS is a method 
that enables the performance of several diagnostic tests 
from one collection, reduces the number of necessary 
visits to one in precolposcopy stage and eliminates the 
use of aerosol fixer.
Liquid-based screening should only use clinically val-
idated tools: liquid media, molecular tests for 14 high-risk 
human papillomavirus types (HRHPV14), separately for the 
primary HRHPV14 test and for the cotesting [10], and for the 
immunocytochemical test p16/Ki67 as well [11]. Until vali-
dated diagnostic tools are approved for Polish population, 
it has been temporarily accepted to rely on the appropriate 
registrations of the American Food and Drug Administration 
(FDA), and additionally on the VALGENT (Validation of HPV 
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Genotyping Tests) and Meijer’s protocols for HRHPV14 tests 
[12, 13, 14].
For liquid-based screening, an implementation of the 
HPV-based model is recommended, i.e.:
•	 primary test for HRHPV14 
•	 or cotesting which includes HRHPV14 testing and liq-
uid-based cytology (LBC), with further diagnostic-ther-
apeutic management depending on tests results and, 
in indicated cases, including a past history.
Clinical management based on the HSIL (CIN 3+) risk 
assessment calculated using the current tests results and 
screening history, presented in the ASCCP 2019 (Ameri-
can Society for Colposcopy and Cervical Pathology) recom-
mendations, is temporarily acceptable approach in the di-
agnostic-therapeutic management in Poland. The screening 
history was defined as recent past tests (in the last 5 years) 
and/or treatment for histological HSIL with sub-categori-
zation to CIN 2 and higher (CIN 2+) in the previous 25 years 
[10, 15, 16]. Presented management is applicable only when 
screening tests approved by the FDA are used.
All HRHPV14 positive cases require further diagnostic 
procedures using the histologic HSIL-risk triage test (CIN 
2+), i.e., cytology or p16/Ki67 test. For HPV positive women, 
ICC p16/Ki67 testing should be regarded as an alternative 
reflex test to cytology and as a triage test for abnormal 
cytology result. A laboratory preparation of p16/Ki67 test 
should be carried out using fully automated system only and 
a morphologic evaluation should be performed by trained 
cytopathologist – both are obligatory FDA conditions for 
p16/Ki67 testing [11].
An optional management in the time of a pandemic is 
referring to immediate colposcopy all patients with detected 
HRHPV types 16 and/or 18, and in the cases of using the 
molecular testing with extended genotyping beyond types 
16 and 18 [HPV extended genotyping (HPV-xGT)], referring 
to immediate colposcopy patients with detected HPV type 
31 it is optionally also recommended [17, 18].
Currently, the use of methylation-based methods does 
not have sufficient clinical validation in cervical cancer 
screening [19].
Four basic interim HPV-based screening models are 
recommended for Polish conditions:
•	 screening model 1 — primary HRHPV14 testing
— 1A — with reflex cytology 
— 1B — with reflex p16/Ki67 test
•	 screening model 2 — primary cotesting (HRHPV14 + LBC)
— 2A — without reflex testing
— 2B — with reflex p16/Ki67 test
•	 screening model 3 — primary HRHPV14 extended 
genotyping (in patients with previously unknown 
HRHPV14 status) with reflex cytology
•	 screening model 4 — primary HRHPV14 testing based 
on the ASCCP 2019 recommendations [10, 15, 16]; 
(ASCCP 2019 Recommendations in Polish: Medycyna 
Praktyczna Ginekologia i Położnictwo No. 05 and No. 
06/2020)
The detailed recommended management strategies 
for screening models 1–3 are shown in Figures 1–7 (see 
page 169–172).
Due to the lack of obligatory reporting for the required 
assessment and quality control parameters for liquid-based 
cytology in Poland, including in particular, the percentage 
of individual cytological diagnoses compared to the values 
reported by the College of American Pathologists (CAP), 
cyto-virological correlations (CVC) and cyto-histological 
correlations (CHC), it is recommended to report minimally 
the parameters indicated in the relevant recommendations 
of the COLPOSCOPY 2020 Project (paper in progress).
2. Self-sampling, defined as a self-collection of vaginal 
material by the patient with the use of a dedicated 
brush, is recommended in the primary HPV-based 
screening as the basic tool for cervical cancer screen-
ing for cases when a social distance is necessary and/or 
concerns of secondary cervical cancer prevention re-
cipients related to risk of infection with SARS-CoV-2 vi-
rus occur, which in its extreme form leads to leave of 
screening [20–22].
Due to the lack of sufficiently validated HRHPV14 tests 
in Poland for the self-sampling method, in the cases of 
positive HPV result obtained with this method, a routine 
material sampling from the cervix is necessary (an appoint-
ment and a contact with medical personnel is needed) 
to confirm the positive result on the validated molecular 
HRHPV testing. In the cases of a confirmed positive HRHPV 
result by validated HPV testing, further management is 
described in point No. 1.
All HRHPV14 negative tests results should be confirmed 
with the currently recommended HRHPV14 tests collected 
by qualified medical personnel or with the use of a self-sam-
pling testing approved for Polish population.
3. The self-sampling method is also recommended as a tri-
age tool enabling the reduction of social contacts for 
the continuation of secondary cervical cancer screen-
ing for minor cytological abnormalities [atypical squa-
mous cells of undetermined significance (ASC-US) or 
low-grade squamous intraepithelial lesions (LSIL)], 
according to Polish recommendations 2016 [23]. It is 
applicable, when the original liquid-based cervical mate-
rial obtained during a routine cervical screening is not 
available in the laboratory.
4. In the case of an epidemiological situation allowing the 
cervical sampling by a doctor or midwife, and when 
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a performing liquid-based preparation in not possible, 
a conventional cytology is acceptable screening strategy 
in opportunistic models from public and private funds, 
with further management depending on cytology re-
sults and the availability of diagnostic tests, based on 
the current recommendations [23–25].
It is emphasized that this screening strategy requires the 
patient’s next appointment, especially in the cases of minor 
cytological abnormalities (ASC-US or LSIL) or in the cases of 
unsatisfactory cytology results, which should be considered 
as suboptimal during a pandemic.
5. Expanding a participation of non-gynecologists (gen-
eral practitioners, midwifes and community nurses) in 
secondary cervical cancer prevention, particularly 
in a promoting and education in self-sampling meth-
od is recommended, as an effective screening alterna-
tive tool to sampling performed by medical person-
nel, when patient is unable to participate in a routine 
cervical cancer screening, and/or the strict national 
or regional epidemiological cautions are introduced. 
INTERIM INDICATIONS FOR COLPOSCOPY
The following results are recommended as decision 
parameters in the referral of the patient to colposcopy with 
biopsy within 3 months, regardless of the other tests results:
•	 positive HRHPV 16 and/or 18 and/or 31 type (HPV type 
31 when using the HPV-xGT testing) in the cases of 
unknown patient’s HRHPV status within the last 3 years,
•	 positive HRHPV 16 and/or 18 and/or 31 type (HPV type 
31 when using the HPV-xGT test) detected again after 
12 months in the cases of a patient previously moni-
tored,
•	 positive HRHPV N16/N18 (one or more) or HRHPV 
N16/N18/N31 (one or more) (N16/N18/N31 type in cas-
es of using the HPV-xGT testing) detected again after 
12 months in the cases of a patient previously monitored,
•	 positive p16/Ki67 test result,
•	 atypical squamous cells, cannot exclude high-grade 
squamous intraepithelial lesion (ASC-H), HSIL or atypical 
glandular cells (AGC) cytology results.
If an invasive process is suspected, further diagnostic-ther-
apeutic management must be undertaken immediately.
The possibility of deferral the diagnostic-therapeutic 
management is maintained as allowed, based on the PTGiP 
and PTKiPSM Interim Guidelines of March 22, 2020, with the 
update of May 2, 2020 [7].
SUPPORTING ACTIONS
An effective and quick education of medical doctors (gy-
necologists, general practitioners, pathologists), laboratory 
diagnosticians, community midwives, community nurses 
and other medical workers is recommended as necessary 
for the effective implementation of these interim guide-
lines for secondary cervical cancer prevention in Poland in 
the SARS-CoV-2 pandemic, with a key role of PTKiPSM and 
support of the Cervical Pathology, Colposcopy and Cytology 
Subdivision of PTGiP.
Scientific societies (PTGiP and PTKiPSM) call for an ade-
quate response to the pandemic all of institutions responsi-
ble for secondary cervical cancer prevention financed from 
public funds in Poland, taking into account the presented 
guidelines and the actual epidemiological situation.
The authors of these guidelines emphasize — in line 
with the position of opinion-forming European and Amer-
ican directional authorities [4, 10], the need to use only 
clinically validated liquid-based media in cervical cancer 
screening and HRHPV14 molecular tests, with a dedicated 
specific liquid-based laboratory preparation, independently 
for LBS and self-sampling [10, 21]. This also applies to all 
recent past screening tests, if included in a risk stratification.
The tests registered by the FDA for cervical cancer 
screening using the primary HRHPV14 testing or cotesting 
and screening tests validated with VALGENT or Meijer’s pro-
tocols are tests of temporary choice for use in Poland due to 
the lack of Polish clinical validation for any of these screening 
tests (an organization of tests’ validation in the progress). 
Similarly, when the p16/Ki67 immunocytochemical test is 
used, only automated preparation is recommended with 
evaluation by directionally trained cytopathologist to em-
ploy the FDA registration [11].
Regarding the selfsampling method, until the tests are 
validated for Polish conditions, it is temporarily recommend-
ed to take advantage of Australia and Netherlands expertise 
in support cervical cancer screening by this method. The 
authors of the guidelines also highlight the need to use 
validated tools to collect material from the cervix and/or 
vagina, also in the cases of the self-sampling method [21].
For the colposcopy, the need of its standardization and 
algorithmization according to the colposcopic protocols guide-
lines and the use of Polish colposcopic nomenclature in accor-
dance with the COLPOSCOPY 2020 Project is pointed [5, 6].
Figures 1–7 describing recommended HPV-based 
screening models depending on the primary screening 
tests results are presented below. 
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Screening model 1B — primary HRHPV14 testing with reflex p16/Ki67 test
Figure 2. Management algorithm for the positive primary 14 types of high-risk human papillomavirus test results with reflex p16/Ki67 double 
immunocytochemical test; HRHPV14 — 14 types of high-risk human papillomavirus; HPV — human papillomavirus; 
Screening model 1A — primary HRHPV14 testing with reflex cytology
Figure 1. Management algorithm for positive primary 14 types of high-risk human papillomavirus test results with reflex cytology; HRHPV14 
— 14 types of high-risk human papillomavirus; NILM — negative for intraepithelial lesion or malignancy; ASC-US+ — atypical squamous cells of 
undetermined significance and higher cytological abnormalities; HPV — human papillomavirus; LBC — liquid-based cytology; ASC-US — atypical 
squamous cells of undetermined significance; LSIL — low-grade squamous intraepithelial lesions; ASC-H — atypical squamous cells, cannot 
exclude high-grade squamous intraepithelial lesion; HSIL — high-grade squamous intraepithelial lesions; AGC — atypical glandular cells; SCC 
— squamous cell carcinoma
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Screening model 2A — primary cotesting (HRHPV14 + LBC) without reflex testing
Figure 3. Management algorithm for the cotesting in cases of a positive 14 types of high-risk human papillomavirus test result; HRHPV14 — 14 
types of high-risk human papillomavirus; LBC — liquid-based cytology; NILM — negative for intraepithelial lesion or malignancy; ASC-US+ 
— atypical squamous cells of undetermined significance and higher cytological abnormalities; HPV — human papillomavirus; ASC-US — atypical 
squamous cells of undetermined significance; LSIL — low-grade squamous intraepithelial lesions; ASC-H — atypical squamous cells, cannot 
exclude high-grade squamous intraepithelial lesion; HSIL — high-grade squamous intraepithelial lesions; AGC — atypical glandular cells; SCC 
— squamous cell carcinoma
Screening model 2A — primary cotesting (HRHPV14 + LBC) without reex testing
Figure 4. Management algorithm for the cotesting in cases of negative 14 types of high-risk human papillomavirus test result; HRHPV14 — 14 
types of high-risk human papillomavirus; LBC — liquid-based cytology; NILM — negative for intraepithelial lesion or malignancy; ASC-US 
— atypical squamous cells of undetermined significance; LSIL — low-grade squamous intraepithelial lesions; ASC-H — atypical squamous cells, 
cannot exclude high-grade squamous intraepithelial lesion; HSIL — high-grade squamous intraepithelial lesions; AGC — atypical glandular cells; 
SCC — squamous cell carcinoma
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Screening model 2B — primary cotesting (HRHPV14 + LBC) with reflex p16/Ki67
Figure 5. Management algorithm for the positive 14 types of high-risk human papillomavirus test results obtained in cotesting with reflex 
p16/Ki67 double immunocytochemical test; HRHPV14 — 14 types of high-risk human papillomavirus; HPV — human papillomavirus; LBC 
— liquid-based cytology; NILM — negative for intraepithelial lesion or malignancy; ASC-US+ — atypical squamous cells of undetermined 
significance and higher cytological abnormalities; ASC-US — atypical squamous cells of undetermined significance; LSIL — low-grade squamous 
intraepithelial lesions; ASC-H — atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; HSIL — high-grade 
squamous intraepithelial lesions; AGC — atypical glandular cells; SCC — squamous cell carcinoma
Screening model 2B — primary cotesting (HRHPV14 + LBC) with reex p16/Ki67
Figure 6. Management algorithm for the negative 14 types of high-risk human papillomavirus test results obtained in cotesting with reflex 
p16/Ki67 double immunocytochemical test; HRHPV14 — 14 types of high-risk human papillomavirus; LBC — liquid-based cytology; NILM 
— negative for intraepithelial lesion or malignancy; ASC-US — atypical squamous cells of undetermined significance; LSIL — low-grade squamous 
intraepithelial lesions; ASC-H — atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; HSIL — high-grade 
squamous intraepithelial lesions; AGC — atypical glandular cells; SCC — squamous cell carcinoma
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Screening model 3 — primary HRHPV14 extended genotyping with reex cytology
Figure 7. Management algorithm for the primary 14 types of high-risk human papillomavirus extended genotyping results with reflex cytology; 
HPV-xGT — human papillomavirus extended genotyping; HPV — human papillomavirus; LSIL — low-grade squamous intraepithelial lesions; 
LBC — liquid-based cytology; NILM — negative for intraepithelial lesion or malignancy; ASC-US — atypical squamous cells of undetermined 
significance
The above guidelines are not the final diagnostic man-
agement approach for abnormal screening tests results 
in secondary cervical cancer prevention. 
They are not a substitute for a complete clinical evalu-
ation of an individual case.
They should always be analyzed in the context of opti-
mizing the diagnostic management in the patient’s health 
interest.
They may be modified depending on changing con-
ditions.
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